                         SEQUENCE LISTING

<110>  Anthrogenesis Corporation
 
<120>  CHIMERIC ANTIGEN RECEPTORS

<130>  12827-401-228

<140>  
<141>  

<150>  61/740,113
<151>  2012-12-20


<150>  61/779,925
<151>  2013-03-13

<160>  11     

<170>  PatentIn version 3.5

<210>  1
<211>  36
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain 

<400>  1

Pro Glu Pro Cys Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala 
1               5                   10                  15      


Val Ser Ser Gly Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser 
            20                  25                  30          


Leu Ser Lys Met 
        35      


<210>  2
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain 

<400>  2

Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly 
1               5                   10                  15      


Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu 
            20                  25                  


<210>  3
<211>  23
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain 

<400>  3

Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr 
1               5                   10                  15      


Ser Phe Leu Leu Thr Ala Val 
            20              


<210>  4
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain 

<400>  4

Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr 
1               5                   10                  15      


Ser Phe Leu Leu Thr 
            20      


<210>  5
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain 

<400>  5

Phe Leu Leu Trp Ile Leu Val Ala Val Ser Leu Gly Leu Phe Phe Tyr 
1               5                   10                  15      


Ser Phe Leu Val Ser Ala Val Ser Leu Ser 
            20                  25      


<210>  6
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - PD-1 transmembrane domain 

<400>  6

Thr Leu Val Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu Val Leu 
1               5                   10                  15      


Leu Val Trp Val Leu Ala Val Ile Cys Ser Arg Ala Ala 
            20                  25                  


<210>  7
<211>  21
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - PD-1 transmembrane domain 

<400>  7

Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu Val Leu Leu Val Trp 
1               5                   10                  15      


Val Leu Ala Val Ile 
            20      


<210>  8
<211>  26
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - PD-1 transmembrane domain 

<400>  8

Phe Gln Thr Leu Val Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu 
1               5                   10                  15      


Val Leu Leu Val Trp Val Leu Ala Val Ile 
            20                  25      


<210>  9
<211>  49
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain

<400>  9

Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val Ile Asp Pro Glu Pro 
1               5                   10                  15      


Ser Pro Asp Ser Asp Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser 
            20                  25                  30          


Gly Leu Phe Phe Tyr Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys 
        35                  40                  45              


Met 
    


<210>  10
<211>  28
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - CTLA4 transmembrane domain

<400>  10

Phe Leu Leu Trp Ile Leu Ala Ala Val Ser Ser Gly Leu Phe Phe Tyr 
1               5                   10                  15      


Ser Phe Leu Leu Thr Ala Val Ser Leu Ser Lys Met 
            20                  25              


<210>  11
<211>  31
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  synthetic peptide - PD-1 transmembrane domain

<400>  11

Phe Gln Thr Leu Val Val Gly Val Val Gly Gly Leu Leu Gly Ser Leu 
1               5                   10                  15      


Val Leu Leu Val Trp Val Leu Ala Val Ile Cys Ser Arg Ala Ala 
            20                  25                  30     
